Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AirSculpt Technologies (NASDAQ: AIRS) transforms unwanted fat into sleek contours—but its SEC disclosures can be far less streamlined. From detailed clinic economics to patented plasma technology risks, each filing packs information investors need to gauge growth and litigation exposure.
Stock Titan’s AI makes understanding AirSculpt Technologies SEC documents with AI straightforward. Our system tags every AirSculpt Technologies quarterly earnings report 10-Q filing, surfaces procedure-volume KPIs, and flags liquidity metrics in seconds. Real-time alerts let you follow AirSculpt Technologies insider trading Form 4 transactions the moment executives buy or sell shares, answering the common question, “Is management adding to their position?”
Here’s what you’ll uncover faster than scrolling through EDGAR:
- 10-K annual report simplified: AI pinpoints new-center roll-out costs, malpractice insurance provisions, and competitive landscape discussion.
- 8-K material events explained: immediate summaries of clinical study outcomes, financing updates, or leadership changes.
- Form 4 insider transactions real-time: visual trend charts of executive stock moves.
- Proxy statement executive compensation: see how incentive plans tie to clinic openings and same-store revenue.
Whether you search, “How do I read AirSculpt’s 10-K annual report?” or “Track AirSculpt Technologies executive stock transactions Form 4,” our platform answers instantly. Every filing is updated the moment it hits EDGAR, then distilled into concise language—so you can compare quarter-over-quarter margins, monitor risk factors, and act on insights before the market digests hundreds of pages.
AirSculpt Technologies, Inc. Schedule 13G/A discloses that a group led by Vesey Street holds a large, concentrated position in the company’s common stock (CUSIP 009496100). The filing reports that Adam T. Feinstein and affiliated entities together hold 30,324,180 shares, or 48.6% of the outstanding common stock. Ownership is allocated across entities: VSCP EBS Aggregator, L.P. (14,038,819 shares, 22.5%), Vesey Street Capital Partners Healthcare Fund-A, L.P. (4,523,899 shares, 7.2%), and EBS Aggregator Blocker Holdings, LLC (11,761,462 shares, 18.8%).
The reporting persons state they possess shared voting and dispositive power over these shares while asserting no sole voting or dispositive power. The percentage calculations are stated to be based on 62,436,670 shares outstanding as of July 31, 2025, per the issuer’s unaudited condensed consolidated financial statements. The filing explains Mr. Feinstein’s management roles through the Vesey Street organizational structure and notes that each reporting person disclaims beneficial ownership beyond its pecuniary interest.
AirSculpt Technologies (AIRS) Q2-25 10-Q highlights:
- Revenue: $44.0 m, -14% YoY; H1-25 revenue $83.4 m, -15% YoY.
- Case volume: 3,392 for the quarter (-14%); revenue per case stable at ~$12.9k.
- Profitability: Adj. EBITDA $5.8 m (13.3% margin vs. 13.5% LY); GAAP net loss $(0.6) m vs. $(3.2) m LY. H1 net loss $(3.4) m.
- Cost actions: Advertising down $3.7 m; $3 m annual overhead cuts; de-novo expansion paused.
- Capital & liquidity: Cash $8.2 m; term-loan $58.8 m (rate 7.8%); leverage covenant amended in Mar-25; $10 m debt pre-payment on 13-Jun-25 funded by $14 m follow-on equity offering (3.6 m shares at $3.80).
- ATM program: 0.12 m shares sold YTD for $0.3 m.
- Balance sheet: Total assets $198.4 m; stockholders’ equity $91.2 m; net debt ~$50.6 m.
- Guidance/strategy: Management focusing on marketing ROI, sales training, new financing options, product innovation and standalone skin-tightening; aims to stabilize same-center performance amid industry softness.
Key risks include declining demand, leverage (LT debt/Adj. EBITDA ≈ 5.0x), tighter covenants, and rising interest margin from July 2025.
FAQ
What is the current stock price of Airsculpt Technologies (AIRS)?
What is the market cap of Airsculpt Technologies (AIRS)?
